CPA Platform in Metabolic Diseases

About InnoSIGN

InnoSIGN is a private, pre-revenue diagnostics platform company developing a proprietary bioinformatics solution for disease interpretation. Its Comprehensive Pathway Analysis (CPA) platform uses a proprietary algorithm to analyze RNA-sequencing data, inferring the activity of key cell signaling pathways to provide deeper, actionable insights beyond single mutations. The platform is positioned to support the full drug development continuum, from preclinical research to companion diagnostics, primarily in oncology but also in autoimmune and metabolic diseases. The company seeks to address the industry's reliance on single biomarkers by offering a systems-level view of disease mechanisms.

Therapeutic Areas

Other Metabolic Diseases Drugs